| Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma RRMKS Muhammad Zubair Afzal Journal for ImmunoTherapy of Cancer 6 (64), 2018 | 142 | 2018 |
| The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized … Y Xu, B Wan, X Chen, P Zhan, Y Zhao, T Zhang, H Liu, MZ Afzal, ... Translational Lung Cancer Research 8 (4), 413, 2019 | 115 | 2019 |
| Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors MZ Afzal, K Dragnev, T Sarwar, K Shirai Lung Cancer Management, 2019 | 67 | 2019 |
| Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study H Duan, T Wang, Z Luo, L Tong, X Dong, Y Zhang, MZ Afzal, P Correale, ... Translational lung cancer research 10 (2), 1020, 2021 | 42 | 2021 |
| Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab … SK Afzal MZ Melanoma Research, 2018 | 37 | 2018 |
| Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone RMKS Muhammad Zubair Afzal Journal for ImmunoTherapy of Cancer 6 (13), 2018 | 31 | 2018 |
| A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous … MZ Afzal, K Dragnev, K Shirai Journal of Thoracic Disease 10 (6), 3575, 2018 | 29 | 2018 |
| Spontaneous regression of refractory diffuse large B-cell lymphoma with improvement in immune status with ART in a patient with HIV: a case report and literature review KC Birendra, MZ Afzal, KA Wentland, H Hashmi, S Singh, E Ivan, ... The American journal of case reports 16, 347, 2015 | 20 | 2015 |
| What impact do the proton pump inhibitors have on the efficacy of immune check point inhibitors in metastatic malignant melanoma? KS Muhammad Zubair Afzal Journal of Clinical Oncology, 2019 | 18 | 2019 |
| Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors MZ Afzal, T Sarwar, K Shirai Journal of Immunotherapy, 2019 | 15 | 2019 |
| Utility of Lower Extremity Doppler in Patients with Lower Extremity Cellulitis: A Need to Change the Practice? LR Afzal MZ, Saleh MM, Razvi S, Hashmi H Southern Medical Journal 108 (7), 439-444, 2015 | 14 | 2015 |
| Osteonecrosis of jaw with the use of denosumab NH Akhtar, MZ Afzal, AAA Ahmed Journal of Cancer Research and Therapeutics 7 (4), 499-500, 2011 | 14 | 2011 |
| Modification of Technique for Suprapubic Catheter Placement After Robot-assisted Radical Prostatectomy Reduces Catheter-associated Complications. LBR Afzal MZ, Tobert CM, Bulica E, Noyes SL Urology, 2015 | 11 | 2015 |
| Does denosumab offer survival benefits?—Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors Y Cao, MZ Afzal, K Shirai Journal of Thoracic Disease 13 (8), 4668, 2021 | 10 | 2021 |
| Tumor molecular profiling in the treatment of refractory cancers. B KC, MZ Afzal, A Sochaki, KA Wentland, R Chang, S Singh, T O'Rourke Journal of Experimental Therapeutics & Oncology 11 (1), 2015 | 7 | 2015 |
| Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a … K Afzal, Muhammad Zubair, Shirai Journal of Immunotherapy, 2019 | 6 | 2019 |
| An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer MZ Afzal, KH Dragnev, K Shirai Annals of Translational Medicine 7 (Suppl 1), 2019 | 5 | 2019 |
| A retrospective analysis of tolerance and outcomes of cutaneous malignant melanoma in patients receiving adjuvant interferon-alpha 2B: a community oncology perspective MZ Afzal, V Pinnamaneni, KC Birendra, AT Davis, TJ Koehler, N Lakhani J Exp Ther Oncol 11 (2), 91-96, 2017 | 5 | 2017 |
| Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma Y Cao, MZ Afzal, K Shirai BMJ Case Reports CP 14 (8), e243713, 2021 | 2 | 2021 |
| Baseline systemic inflammatory immune index may predict overall survival and progression-free survival in patients with non-small cell lung cancer patients on immune checkpoint … JP Palmer, Y Cao, S Ibrahim, N Dhawan, MZ Afzal, K Shirai Journal of Clinical Oncology 39 (15_suppl), e21202-e21202, 2021 | 2 | 2021 |
